Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single- and multiple-ascending-dose study of THN391 in healthy volunteers
NL-OMON59558Phase 1Completed
- Sponsor
- Therini Bio
- Start
- Apr 2023
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing THN391 ascending dose with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Apr 2023; status: completed.
02
Drugs
THN391
Beyond the preview
Go deeper on NL-OMON59558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59558.